Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 2022-11-16 21:00
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement 2022-05-18 20:00
BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission 2021-09-28 20:00
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins 2021-09-23 15:00
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration 2021-09-07 20:00
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans 2021-08-03 20:00
BioVaxys Announces Non-Brokered Private Placement 2021-06-29 10:46
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T 2021-03-31 20:00
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production 2021-02-18 21:00
BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program 2021-01-25 21:00
1